Loading...

Mirum Pharmaceuticals, Inc.

MIRMNASDAQ
Healthcare
Biotechnology
$51.83
$-0.34(-0.65%)

Mirum Pharmaceuticals, Inc. (MIRM) Company Profile & Overview

Explore Mirum Pharmaceuticals, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Mirum Pharmaceuticals, Inc. (MIRM) Company Profile & Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

SectorHealthcare
IndustryBiotechnology
CEOChristopher Peetz

Contact Information

650 667 4085
950 Tower Lane, Foster City, CA, 94404

Company Facts

334 Employees
IPO DateJul 18, 2019
CountryUS
Actively Trading

Frequently Asked Questions

;